NextCure (NXTC)

• Market cap: $19.3M
• 1 day: -4.32%
• 5 days: -4.32%
• 1 month: -9.03%
• 3 months: -31.79%
• 6 months: -48.20%
• Year to date: -16.19%
• 1 year: -53.14%
• 5 years: -98.06%
• 10 years: -96.54%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Employees: 43

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

5% more funds holding

Funds holding: 44 [Q3] → 46 (+2) [Q4]

0.54% more ownership

Funds ownership: 56.7% [Q3] → 57.25% (+0.54%) [Q4]

40% less capital invested

Capital invested by funds: $21.7M [Q3] → $13.1M (-$8.6M) [Q4]

54% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 13

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 335% upside
• Avg. target: $3 335% upside
• High target: $3 335% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 19% 1-year accuracy 29 / 156 met price target

335% upside $3

Buy Reiterated

7 Mar 2025